Preoperative β-Blockade with Propranolol Reduces Biomarkers of Metastasis in Breast Cancer: A Phase II Randomized Trial.
Jonathan G HillerSteven W ColeElizabeth M CroneDavid J ByrneDavid M ShacklefordJia-Min B PangMichael A HendersonSophie S NightingaleKwok M HoPaul S MylesStephen B FoxBernhard RiedelErica K SloanPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
One week of β-blockade with propranolol reduced intratumoral mesenchymal polarization and promoted immune cell infiltration in early-stage surgically-resectable breast cancer. These results show that β-blockade reduces biomarkers associated with metastatic potential, and support the need for larger phase III clinical trials powered to detect the impact of β-blockade on cancer recurrence and survival.See related commentary by Blaes et al., p. 1781.